Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy

Background This retrospective study focused on analyzing community-acquired respiratory virus (CARV) infections, in particular human parainfluenza virus (hPIV) after allogeneic stem cell transplant (allo-SCT) in adults recipients. It aimed to assess the impact of ribavirin treatment, clinical charac...

Full description

Saved in:
Bibliographic Details
Published in:Infection 2024-10, Vol.52 (5), p.1941-1952
Main Authors: Pérez, Ariadna, Montoro, Juan, Chorão, Pedro, Gómez, Dolores, Guerreiro, Manuel, Giménez, Estela, Villalba, Marta, Sanz, Jaime, Hernani, Rafael, Hernández-Boluda, Juan Carlos, Lorenzo, Ignacio, Navarro, David, Solano, Carlos, Ljungman, Per, Piñana, José Luis
Format: Article
Language:English
Subjects:
Adult
Aged
Allografts
Antiviral Agents - therapeutic use
Cell number
Community-Acquired Infections - drug therapy
Community-Acquired Infections - mortality
Community-Acquired Infections - virology
Corticoids
Corticosteroids
Family Medicine
Female
Fever
General Practice
Health services
Humans
Impact analysis
Infections
Infectious Diseases
Internal Medicine
Lymphocytes
Male
Medicin och hälsovetenskap
Medicine
Medicine & Public Health
Middle Aged
Mortality
Multivariate analysis
Parainfluenza
Paramyxoviridae Infections - drug therapy
Paramyxoviridae Infections - mortality
Respiratory tract
Respiratory tract diseases
Retrospective Studies
Ribavirin
Ribavirin - therapeutic use
Risk Factors
Stem cell transplantation
Stem Cell Transplantation - adverse effects
Stem cells
Steroids
Therapy
Transplantation, Homologous - adverse effects
Transplants & implants
Treatment Outcome
Viruses
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background This retrospective study focused on analyzing community-acquired respiratory virus (CARV) infections, in particular human parainfluenza virus (hPIV) after allogeneic stem cell transplant (allo-SCT) in adults recipients. It aimed to assess the impact of ribavirin treatment, clinical characteristics, and risk factors associated with lower respiratory tract disease (LRTD) progression and all-cause mortality. Patients and methods The study included 230 allo-SCT recipients diagnosed with hPIV between December 2013 and June 2023. Risk factors for the development of LRTD, disease severity, and mortality were analyzed. Ribavirin treatment was administered at physician discretion in 61 out of 230 cases (27%). Results Risk factors for LRTD progression in multivariate analysis were corticosteroids > 30 mg/day (Odds ratio (OR) 3.5, 95% Confidence Interval (C.I.) 1.3–9.4, p  = 0.013), fever at the time of hPIV detection (OR 3.89, 95% C.I. 1.84–8.2, p  
ISSN:0300-8126
1439-0973
1439-0973
DOI:10.1007/s15010-024-02213-0